Tech Company M&A Transactions

Biscayne Therapeutics Acquisition

On 9/18/2018, Biscayne Therapeutics was acquired by Supernus Pharmaceuticals. Supernus Pharmaceuticals said the transaction price was $183 million.

Transaction Overview

Announced On
Transaction Type
M&A Terms
The transaction, expected to close in the next few weeks, provides for an upfront payment of $15 million payable by Supernus to the current Biscayne security holders. Additional payments payable by Supernus include $73 million contingent on achieving certain development milestones and up to $95 million contingent upon achieving certain sales milestones. Supernus will pay a low single digit royalty on net sales to Biscayne and any applicable royalties to third parties for the use of in-licensed IP. The maximum combined royalty Supernus will pay to all parties is approximately 12%, depending on the IP covering the marketed product and the applicable tiered sales levels.

Company Information

Company Status
Acquired or Merged
Mailing Address
4770 Biscayne Blvd. 660
Miami, FL 33137
Email Address
Biscayne Pharmaceuticals is developing novel drugs for cancer and other serious disorders based on analogs of growth hormone-releasing hormone (GHRH) discovered by Dr. Andrew V. Schally, Nobel laureate and renowned drug researcher.
Biscayne Therapeutics LinkedIn Company Profile
Social Media
Biscayne Therapeutics Company Twitter Account
Company News
Biscayne Therapeutics News
Biscayne Therapeutics on Facebook
Biscayne Therapeutics on YouTube

Management Team

Email & Social
Samuel Reich
  Samuel Reich LinkedIn Profile  Samuel Reich Twitter Account  Samuel Reich News  Samuel Reich on Facebook
Chief Executive Officer
Stephen Collins
  Stephen Collins LinkedIn Profile  Stephen Collins Twitter Account  Stephen Collins News  Stephen Collins on Facebook
VP - Finance
Jared Mendel
  Jared Mendel LinkedIn Profile  Jared Mendel Twitter Account  Jared Mendel News  Jared Mendel on Facebook
VP - R & D
Peter Goldstein
  Peter Goldstein LinkedIn Profile  Peter Goldstein Twitter Account  Peter Goldstein News  Peter Goldstein on Facebook
VP - R & D
Joshua Johnstone
  Joshua Johnstone LinkedIn Profile  Joshua Johnstone Twitter Account  Joshua Johnstone News  Joshua Johnstone on Facebook



Browse more venture capital transactions:

Prev: 9/18/2018: SCYTHE venture capital transaction
Next: 9/18/2018: Blippar venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary